Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Amylin Pharmaceuticals (Nasdaq: AMLN ) shares bounced 10% today on an upgrade from analysts at Leerink Swann.
So what: Amylin saw its stock drop 50% last week when regulators declined to approve Bydureon. The stock may have oversold on that news, and analysts think it still has upside even with a longer lead time on the diabetes treatment.
Now what: Bydureon still has a long road ahead and this Fool never likes buying because an analyst says so. This looks like a typical upgrade bump to me, without any solid news from the company. I'm selling the move today given the long-term uncertainty surrounding Bydureon.
Interested in more info on Amylin Pharmaceuticals? Add it to your watchlist here by clicking here.